In a recent study conducted by Lin et al., anti-EGFR and anti-FAP bispecific antibody-targeted liposomal irinotecan was developed to target pancreatic cancer cells and tumor fibroblasts [100]. The gene discussed is FAP; the disease is pancreatic neoplasm.